Oruka Therapeutics, Inc.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $43.3M | — | $29.1M | — | — | — | $29.0M |
| SG&A Expense | — | $6.9M | — | $7.3M | — | — | — | $5.1M |
| Operating Income | — | $-50.1M | — | $-36.4M | — | — | — | $-34.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-41.2M | — | $-31.8M | — | — | — | $-30.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 66.2M | 61.1M | 60.3M | 50.2M | 49.5M | 48.7M | 48.4M | 48.4M |
| Shares Outstanding (Diluted) | 66.2M | 61.1M | 60.3M | 50.2M | 49.5M | 48.7M | 48.4M | 48.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |